These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 23396081)

  • 1. Targeting the SYK-BTK axis for the treatment of immunological and hematological disorders: recent progress and therapeutic perspectives.
    Tan SL; Liao C; Lucas MC; Stevenson C; DeMartino JA
    Pharmacol Ther; 2013 May; 138(2):294-309. PubMed ID: 23396081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a pharmacodynamic assay based on PLCγ2 phosphorylation for quantifying spleen tyrosine kinase (SYK)-Bruton's tyrosine kinase (BTK) signaling.
    Hsu J; Zhang J; Kitson C; Tan SL; Narula S; DeMartino JA; Liao C
    J Biomol Screen; 2013 Sep; 18(8):890-8. PubMed ID: 23704133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy.
    Liao C; Hsu J; Kim Y; Hu DQ; Xu D; Zhang J; Pashine A; Menke J; Whittard T; Romero N; Truitt T; Slade M; Lukacs C; Hermann J; Zhou M; Lucas M; Narula S; DeMartino J; Tan SL
    Arthritis Res Ther; 2013 Oct; 15(5):R146. PubMed ID: 24286216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting spleen tyrosine kinase-Bruton's tyrosine kinase axis for immunologically mediated glomerulonephritis.
    Chen JS; Chang LC; Huang SJ; Cheng CW
    Biomed Res Int; 2014; 2014():814869. PubMed ID: 24795896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders.
    Robak T; Robak E
    Expert Opin Investig Drugs; 2012 Jul; 21(7):921-47. PubMed ID: 22612424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.
    Coffey G; DeGuzman F; Inagaki M; Pak Y; Delaney SM; Ives D; Betz A; Jia ZJ; Pandey A; Baker D; Hollenbach SJ; Phillips DR; Sinha U
    J Pharmacol Exp Ther; 2012 Feb; 340(2):350-9. PubMed ID: 22040680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small-molecule inhibitors of spleen tyrosine kinase as therapeutic agents for immune disorders: will promise meet expectations?
    Lucas MC; Tan SL
    Future Med Chem; 2014; 6(16):1811-27. PubMed ID: 25407369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spleen tyrosine kinase inhibitors: a review of the patent literature 2010 - 2013.
    Norman P
    Expert Opin Ther Pat; 2014 May; 24(5):573-95. PubMed ID: 24555683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.
    Robak T; Robak P
    Int Rev Immunol; 2013 Aug; 32(4):358-76. PubMed ID: 23617253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities.
    Hill RJ; Lou Y; Tan SL
    Int Rev Immunol; 2013 Aug; 32(4):377-96. PubMed ID: 23886341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas.
    Uckun FM; Qazi S
    Expert Rev Anticancer Ther; 2010 Sep; 10(9):1407-18. PubMed ID: 20836676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
    Friedberg JW; Sharman J; Sweetenham J; Johnston PB; Vose JM; Lacasce A; Schaefer-Cutillo J; De Vos S; Sinha R; Leonard JP; Cripe LD; Gregory SA; Sterba MP; Lowe AM; Levy R; Shipp MA
    Blood; 2010 Apr; 115(13):2578-85. PubMed ID: 19965662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors of switch kinase 'spleen tyrosine kinase' in inflammation and immune-mediated disorders: a review.
    Kaur M; Singh M; Silakari O
    Eur J Med Chem; 2013 Sep; 67():434-46. PubMed ID: 23917087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel small molecule therapeutics in rheumatoid arthritis.
    Kelly V; Genovese M
    Rheumatology (Oxford); 2013 Jul; 52(7):1155-62. PubMed ID: 23297340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic prospect of Syk inhibitors.
    Ruzza P; Biondi B; Calderan A
    Expert Opin Ther Pat; 2009 Oct; 19(10):1361-76. PubMed ID: 19670961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A targeted therapy for protein and lipid kinases in chronic lymphocytic leukemia.
    Robak P; Robak T
    Curr Med Chem; 2012; 19(31):5294-318. PubMed ID: 22830347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia.
    Wu H; Hu C; Wang A; Weisberg EL; Chen Y; Yun CH; Wang W; Liu Y; Liu X; Tian B; Wang J; Zhao Z; Liang Y; Li B; Wang L; Wang B; Chen C; Buhrlage SJ; Qi Z; Zou F; Nonami A; Li Y; Fernandes SM; Adamia S; Stone RM; Galinsky IA; Wang X; Yang G; Griffin JD; Brown JR; Eck MJ; Liu J; Gray NS; Liu Q
    Leukemia; 2016 Jan; 30(1):173-81. PubMed ID: 26165234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Syk kinase as a therapeutic target in leukemia and lymphoma.
    Efremov DG; Laurenti L
    Expert Opin Investig Drugs; 2011 May; 20(5):623-36. PubMed ID: 21438742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Syk kinase as a treatment target for therapy in autoimmune diseases.
    Kyttaris VC; Tsokos GC
    Clin Immunol; 2007 Sep; 124(3):235-7. PubMed ID: 17662659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma.
    Balsas P; Esteve-Arenys A; Roldán J; Jiménez L; Rodríguez V; Valero JG; Chamorro-Jorganes A; de la Bellacasa RP; Teixidó J; Matas-Céspedes A; Moros A; Martínez A; Campo E; Sáez-Borderías A; Borrell JI; Pérez-Galán P; Colomer D; Roué G
    J Hematol Oncol; 2017 Mar; 10(1):80. PubMed ID: 28359287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.